Last10K.com

Nexien Biopharma, Inc. (NXEN) SEC Filing 10-K Annual report for the fiscal year ending Sunday, June 30, 2019

Nexien Biopharma, Inc.

CIK: 1625288 Ticker: NXEN
Document and Entity Information - USD ($)
12 Months Ended
Jun. 30, 2019
Sep. 25, 2019
Dec. 31, 2018
Document And Entity Information   
Entity Registrant NameNEXIEN BIOPHARMA, INC.  
Entity Central Index Key0001625288  
Document Type10-K  
Document Period End DateJun. 30, 2019  
Amendment Flagfalse  
Current Fiscal Year End Date--06-30  
Entity a Well-known Seasoned IssuerNo  
Entity a Voluntary FilerNo  
Entity Reporting Status CurrentYes  
Entity Interactive Data CurrentYes  
Entity Filer CategoryNon-accelerated Filer  
Entity Small Business Flagtrue  
Entity Emerging Growth Companytrue  
Entity Ex Transition Periodfalse  
Entity Shell Companyfalse  
Entity Public Float  $ 2,826,071
Entity Common Stock, Shares Outstanding 53,984,004 
Document Fiscal Period FocusFY  
Document Fiscal Year Focus2019  

View differences made from one year to another to evaluate Nexien Biopharma, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Nexien Biopharma, Inc..

Continue

Assess how Nexien Biopharma, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Nexien Biopharma, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statement Of Stockholders' Equity
Consolidated Statement Of Stockholders' Equity (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Commitments And Contingencies
Income Taxes
Income Taxes (Details Narrative)
Income Taxes (Tables)
Income Taxes - Schedule Of Deferred Tax Asset And Valuation Account (Details)
Income Taxes - Schedule Of Deferred Tax Asset And Valuation Account (Details) (Parenthetical)
Income Taxes - Schedule Of Income Tax Expense (Details)
License Agreements
License Agreements (Details Narrative)
Nature Of Business And Basis Of Presentation
Nature Of Business And Basis Of Presentation (Details Narrative)
Prepaid Expenses
Prepaid Expenses (Tables)
Prepaid Expenses - Schedule Of Prepaid Expenses (Details)
Related Party Transactions
Related Party Transactions (Details Narrative)
Share Exchange Agreement
Share Exchange Agreement (Details Narrative)
Stockholders' Equity
Stockholders' Equity (Details Narrative)
Stockholders' Equity (Tables)
Stockholders' Equity - Schedule Of Common Stock From The Exercise Of Warrants (Details)
Stockholders' Equity - Schedule Of Fair Value Of Stock Options Assumptions (Details)
Stockholders' Equity - Schedule Of Stock Option Activity (Details)
Stockholders' Equity - Summary Of Warrant Activity (Details)
Subsequent Events
Subsequent Events (Details Narrative)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)

Material Contracts, Statements, Certifications & more

Nexien Biopharma, Inc. provided additional information to their SEC Filing as exhibits

Ticker: NXEN
CIK: 1625288
Form Type: 10-K Annual Report
Accession Number: 0001493152-19-014714
Submitted to the SEC: Mon Sep 30 2019 6:06:17 AM EST
Accepted by the SEC: Mon Sep 30 2019
Period: Sunday, June 30, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/nxen/0001493152-19-014714.htm